A combined PAX1/JAM3 methylation and HPV viral load model for exploratory risk stratification of ≥CIN2 among women with positive cervical screening results
Aug 2026· BMC Cancer· Vol 26· 0 citations· 34 references
Medicine
TL;DR
Combining PAX1/JAM3 methylation with HPV viral load may refine ≥CIN2 risk stratification among women with positive cervical screening results, particularly among women with ASCUS.
Abstract
High-risk human papillomavirus (Hr-HPV) testing is highly sensitive for cervical cancer screening but lacks specificity, leading to unnecessary colposcopy referrals. Host-gene methylation and HPV viral load capture different aspects of disease risk and may support triage. In this prospective real-world triage cohort, 126 women with Hr-HPV positivity and/or abnormal cervical cytology identified through opportunistic cervical screening and clinical referral were enrolled. All participants underwent cytology, HPV genotyping with viral load quantification, and PAX1/JAM3 methylation testing. Histopathology served as the reference standard. A logistic regression model integrating methylation status and viral load was constructed to evaluate its performance for detecting ≥CIN2, with subgroup analysis in ASCUS. Methylation levels, expressed as ΔCt values, decreased with increasing lesion severity and were associated with HPV viral load. In the overall screening-positive cohort, the logistic regression model discriminated ≥CIN2 better than either marker alone. In the ASCUS subgroup, the biomarker-only logistic regression model showed the highest observed AUC among the three evaluated approaches, although this subgroup finding remained exploratory. Scenario-specific strategies showed different trade-offs: the OR rule provided higher sensitivity, whereas the AND rule improved specificity but had lower sensitivity and should be interpreted as a confirmatory triage approach rather than a stand-alone screening rule. Combining PAX1/JAM3 methylation with HPV viral load may refine ≥CIN2 risk stratification among women with positive cervical screening results, particularly among women with ASCUS. However, given the referral-enriched nature, limited sample size, and single-center design, the clinical applicability of this approach requires validation in larger, more representative cohorts.
Hybrid Capture 2 (HC2) provides a semi-quantitative estimate of high-risk human papillomavirus (HPV) burden as relative light units/cutoff (RLU/CO), and HPV genotyping may add value to triage assessment. We evaluated the association of RLU/CO with cervical lesion severity and explored whether genotype information i...
Nilanchali Singh, Zakiya Zakiya, Seema Singhal et al.· Frontiers in Global Women's...· 0 citations
Spontaneous regression of CIN2 is more frequent in women with non-HPV16 infection and negative FAM19A4/miR124-2 methylation, and a combination of these markers improves identification of women with lower risk of disease progression and supports safer implementation of active surveillance and conservative management.
Milena Mikluš, M. Poljak, J. Mlakar et al.· Journal of Medical Virology· 0 citations
PA1/JAM3 dual-gene methylation testing demonstrates high diagnostic accuracy for detecting high-grade cervical intraepithelial neoplasia and cervical cancer, supporting its potential role as a triage biomarker in high-risk human papillomavirus positive women.
Persistent post-treatment ctDNA detection was associated with disease progression, supporting the potential role of HPV16 ctDNA in risk-adapted surveillance following curative-intent treatment and providing clinically meaningful prognostic information in HPV-associated OPC.
L. Torrens, P. Chopard, V. Gaborieau et al.· European Journal of Cancer· 0 citations
Many cervical screening programmes rely on cytology for triage of high-risk human papillomavirus (hrHPV) positive women. However, cytological triage has variable and often limited sensitivity, and its availability can be restricted in resource-poor settings. The Women's cancer risk IDentification cervical intraepitheli...
L. Ellis, Sarah J. Bowden, Jack Tighe et al.· International Journal of Can...· 0 citations
Baseline HPV16 positivity and genotype multiplicity are independent, additive risk factors for HSIL+, with HPV16 plus other HR types marking the highest-risk subgroup, with HPV16 plus other HR types marking the highest-risk subgroup.
B. Gardella, M. Dominoni, M. R. Pano et al.· Gynecologic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.